Holen Sie sich die Stockscreener-App
13.67
1.23%
-0.17
Schlusskurs vom Vortag:
$13.84
Offen:
$14.12
24-Stunden-Volumen:
1.04M
Relative Volume:
1.13
Marktkapitalisierung:
$755.19M
Einnahmen:
$88.24M
Nettoeinkommen (Verlust:
$-160.90M
KGV:
-5.131
EPS:
-2.6642
Netto-Cashflow:
$-129.35M
1W Leistung:
-5.53%
1M Leistung:
-8.50%
6M Leistung:
+44.20%
1J Leistung:
+57.67%
1-Tages-Spanne:
$13.60
$14.13
1-Wochen-Bereich:
$13.60
$14.97
52-Wochen-Spanne:
$6.96
$16.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
13.67 | 799.38M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-11-07 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
4D Molecular Therapeutics Insiders Sold US$757k Of Shares Suggesting Hesitancy - Simply Wall Street
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway - Seeking Alpha
4D Molecular Therapeutics Advances 4D-150 into Phase 3 for Diabetic Macular Edema with Initiation of 4Sight - marketscreener.com
4D Molecular Therapeutics Initiates Patient Enrollment in Phase 3 4SIGHT Trial for Diabetic Macular Edema - Kalkine Media
4D Molecular Therapeutics Begins Phase 3 4D-150 DME Trial - TipRanks
4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema - Yahoo Finance
A 9-person study reported 61% lower injection burden with 4D-150 versus a 13-shot projection. - Stock Titan
4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock By Investing.com - Investing.com Nigeria
Live 4D Molecular Therapeutics, Inc. (FDMT) Technical Analysis - Traders Union
Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 4D Molecular Therapeutics Inc For: 22 September - Investing.com India
Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com India
4D Molecular (FDMT) legal chief exercises options, then sells 1,635 shares - Stock Titan
4D Molecular Therapeutics (Nasdaq:FDMT)Stock Analysis - Simply Wall Street
4D (FDMT) Stock Today: Rallies +5.45%, Resistance at $15.24 2026-09-17Volume Breakout Ideas - careplusvn.com
Insider David Kirn Sells 58,333 Shares of 4D Molecular Therapeutics Inc (FDMT) - GuruFocus
4D molecular therapeutics CEO Kirn sells $811,003 in stock - Investing.com
4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com UK
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing - marketscreener.com
4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial momentum in retinal diseases - TradingView
4D Molecular Therapeutics at Morgan Stanley conference: gene therapy push By Investing.com - Investing.com UK
Insider at 4D Molecular (NASDAQ: FDMT) plans new stock sale after recent trades - Stock Titan
4D Molecular Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
4D Molecular Therapeutics Grants RSUs to Seven New Non-Executive Employees - Quiver Quantitative
Seven new employees get 96,000 stock units from 4DMT - stocktitan.net
4DMT Announces New Employment Inducement Grants - GlobeNewswire
FDMT: Phase III data for 4D-150 in wet AMD and DME expected next year, targeting major treatment shifts - TradingView
FDMT: 4D-150 targets a paradigm shift in wet AMD with major phase III data expected next year - TradingView
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 - investing.com
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan
4DMT to Participate in Upcoming Investor Conferences - Yahoo Finance
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat
4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME - Bitget
4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan
HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media
4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4 D Molecular Therapeutics Inc-Aktie (FDMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer |
Sep 16 '26 |
Sale |
13.65 |
1,635 |
22,318 |
8,617 |
| Kirn David | See Remarks |
Sep 14 '26 |
Sale |
13.90 |
58,333 |
811,004 |
767,486 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):